Cargando…

Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival

INTRODUCTION: Hepatitis B virus (HBV) reactivation has been reported in B-cell lymphoma patients with resolved hepatitis B (hepatitis B surface antigen [HBsAg]-negative and hepatitis B core antibody [HBcAb]-positive). This study aimed to assess HBV reactivation and hepatitis occurrence in diffuse la...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Kai-Lin, Chen, Jie, Rao, Hui-Lan, Guo, Ying, Huang, Hui-Qiang, Zhang, Liang, Shao, Jian-Yong, Lin, Tong-Yu, Jiang, Wen-Qi, Zou, De-Hui, Hu, Li-Yang, Wirian, Michael Lucas, Cai, Qing-Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593350/ https://www.ncbi.nlm.nih.gov/pubmed/26058465 http://dx.doi.org/10.1186/s40880-015-0015-9

Ejemplares similares

Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study
por: Tsai, Yu-Fen, et al.
Publicado: (2019)

Late Hepatitis B reactivation after treatment with rituximab
por: Pereira, Sara Lacerda, et al.
Publicado: (2022)

Capable Infection of Hepatitis B Virus in Diffuse Large B-cell Lymphoma
por: Wang, Yanchun, et al.
Publicado: (2018)

Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(−)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis
por: Kuo, Meng Hsuan, et al.
Publicado: (2020)

Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy
por: Kikuchi, Takaki, et al.
Publicado: (2020)

Primary hepatic diffuse large B cell lymphoma: A case report: Primary hepatic diffuse large B cell lymphoma
por: Ma, Yuan-Ji, et al.
Publicado: (2011)

Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy
por: XIE, WANZHUO, et al.
Publicado: (2013)

Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy
por: Lam, Lok-Ka, et al.
Publicado: (2023)

Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation
por: Lee, Juhan, et al.
Publicado: (2018)

Prophylactic antiviral therapy for hepatitis B virus surface antigen‐positive patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapy
por: Yamauchi, Nobuhiko, et al.
Publicado: (2021)

PB2312: REACTIVATION OF HEPATITIS B VIRUS FOLLOWING RITUXIMAB IN B LYMPHOID HEMOPATHIES
por: Wafa, Miled, et al.
Publicado: (2023)

Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma
por: Wang, Feng, et al.
Publicado: (2008)

Management of Hepatitis B Virus Reactivation in Malignant Lymphoma Prior to Immunosuppressive Treatment
por: Tsai, Yu-Fen, et al.
Publicado: (2021)

Risk of Reactivation of Hepatitis B in Hepatitis B Surface Antigen-Negative and Hepatitis B Core Antigen Antibody Positive Patients Receiving Biologic Therapy
por: Gök Sargın, Zeynep
Publicado: (2023)

Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma
por: Kelling, Matthew, et al.
Publicado: (2018)

Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy
por: Hayashi, Manabu, et al.
Publicado: (2018)

A Hepatitis B Virus Reactivation Case Potentially Triggered by the Onset of Diffuse Large B Cell Lymphoma
por: Sato, Kentaro, et al.
Publicado: (2022)

Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection
por: Tsai, Yu-Fen, et al.
Publicado: (2021)

Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab
por: Schmajuk, Gabriela, et al.
Publicado: (2017)

Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation
por: Elsebaey, Mohamed A., et al.
Publicado: (2022)

Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma
por: Muraishi, Junichi, et al.
Publicado: (2017)

Hepatitis B reactivation in patients with pemphigus vulgaris after immunosuppressive therapy including rituximab
por: Yoo, Dae San, et al.
Publicado: (2020)

Improving testing for hepatitis B before treatment with rituximab
por: Dyson, Jessica K., et al.
Publicado: (2016)

Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin
por: Deng, Lijuan, et al.
Publicado: (2015)

Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome
por: Guo, Ya-fei, et al.
Publicado: (2018)

Hepatitis B and Hepatitis C Reactivation in the Biologic Era
por: Bojito-Marrero, Lizza, et al.
Publicado: (2014)

Fatal Fulminant Hepatitis from Rituximab-induced Hepatitis B Reactivation in a Patient with Follicular Lymphoma: A Case Report and a Brief Review of Literature
por: Khan, Zarak H, et al.
Publicado: (2018)

Terbinafine-Induced Hepatitis B Reactivation in a Patient With Chronic Hepatitis B
por: Shehi, Elona, et al.
Publicado: (2020)

Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab
por: Haider, Mahnur, et al.
Publicado: (2020)

On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B
por: Gao, Yu-Hua, et al.
Publicado: (2016)

Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
por: Xia, Zhengzheng, et al.
Publicado: (2023)

Reactivation of hepatitis B virus with mutated hepatitis B surface antigen in a liver transplant recipient receiving a graft from an antibody to hepatitis B surface antigen– and antibody to hepatitis B core antigen–positive donor
por: Blaich, Annette, et al.
Publicado: (2012)

Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Risk Stratification for Hepatitis B Virus Reactivation in Kidney Transplant Recipients With Resolved HBV Infection
por: Tsai, Hsin-Ju, et al.
Publicado: (2023)

Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China
por: Chen, Dao-guang, et al.
Publicado: (2021)

Primary Hepatic Lymphoma in a Patient with Chronic Hepatitis B
por: Mrabet, Soumaya, et al.
Publicado: (2020)

905. Risk of Hepatitis B Reactivation in Patients Receiving Ibrutinib: The National VA Cohort
por: Chen, Ting-Yi, et al.
Publicado: (2021)

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib
por: Ataca Atilla, Pınar, et al.
Publicado: (2019)

Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment
por: Kuo, Meng Hsuan, et al.
Publicado: (2021)

Genomic and transcriptomic characterization reveals B‐cell hyperactivation and immune evasion in hepatitis B virus‐associated diffuse large B‐cell lymphoma
por: Qin, Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jj5nok1d1pag7o8mdm2i8lr6uu